Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 26, 2023; 11(18): 4350-4359
Published online Jun 26, 2023. doi: 10.12998/wjcc.v11.i18.4350
Nivolumab-induced tumour-like gastritis: A case report
Elena Cijauskaite, Edita Kazenaite, Sandra Strainiene, Goda Sadauskaite, Benediktas Kurlinkus
Elena Cijauskaite, Faculty of Medicine, Vilnius University, Vilnius 01513, Lithuania
Edita Kazenaite, Goda Sadauskaite, Benediktas Kurlinkus, Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius 01513, Lithuania
Edita Kazenaite, Goda Sadauskaite, Benediktas Kurlinkus, Vilnius University Hospital Santaros Clinics, Center of Hepatology, Gastroenterology and Dietology, Vilnius 08661, Lithuania
Sandra Strainiene, Department of Internal Medicine and Surgery, Antakalnis Clinic, Vilnius 10207, Lithuania
Author contributions: Cijauskaite E wrote the original manuscript and reviewed the literature; Kurlinkus B was the gastroenterologist who followed-up the patient, obtained the patient’s informed consent and performed data extraction; Kurlinkus B, Strainiene S reviewed and edited the manuscript; Kurlinkus B, Sadauskaite G and Kazenaite E revised the manuscript for important intellectual content; All authors have read and approved the final manuscript.
Informed consent statement: The patient signed the institution's standard document for informed consent to use her health data for the purpose of this clinical case report.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sandra Strainiene, MD, Attending Doctor, Department of Internal Medicine and Surgery, Antakalnis Clinic, Antakalnis Street 59, Vilnius 10207, Lithuania. sandra.strainiene@gmail.com
Received: February 25, 2023
Peer-review started: February 25, 2023
First decision: April 11, 2023
Revised: April 23, 2023
Accepted: May 9, 2023
Article in press: May 9, 2023
Published online: June 26, 2023
Processing time: 121 Days and 14.1 Hours
Core Tip

Core Tip: Nivolumab-induced gastritis is a less common immune-related adverse event of nivolumab. The most common symptoms include nausea, pain, diarrhea, loss of appetite, and weight loss. Esophagogastroduodenoscopy and biopsy are the most important diagnostic tools. In most cases, gastritis is treated with corticosteroids in combination with proton pump inhibitors. In our case, the patient was successfully treated with omeprazole monotherapy.